Published in J Neurosci on June 15, 1999
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) J Neurol Neurosurg Psychiatry (2000) 1.87
Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging (2005) 1.73
Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers. Neurology (2009) 1.54
MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) (2005) 1.35
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology (2005) 1.30
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) (2004) 1.22
Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users. Drug Alcohol Depend (2008) 1.16
Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharmacology (Berl) (2006) 1.12
Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug Alcohol Depend (2006) 1.08
Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) (2003) 1.07
Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology (Berl) (2003) 1.04
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem (2011) 1.03
Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med (2002) 1.02
Human Ecstasy use is associated with increased cortical excitability: an fMRI study. Neuropsychopharmacology (2011) 0.99
Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) (2003) 0.95
MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) (2004) 0.93
Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) (2005) 0.93
Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) (2004) 0.93
Prospective memory impairment in "ecstasy" (MDMA) users. Psychopharmacology (Berl) (2007) 0.92
Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study. Psychopharmacology (Berl) (2012) 0.91
Deficits of long-term memory in ecstasy users are related to cognitive complexity of the task. Psychopharmacology (Berl) (2010) 0.91
Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) (2004) 0.90
Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users. Psychiatry Res (2007) 0.90
Effects of MDMA on blood glucose levels and brain glucose metabolism. Eur J Nucl Med Mol Imaging (2007) 0.90
Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Arch Gen Psychiatry (2011) 0.89
Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology (Berl) (2011) 0.89
Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharmacology (Berl) (2005) 0.88
Long-term behavioral consequences of prenatal MDMA exposure. Physiol Behav (2008) 0.88
Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study. Psychopharmacology (Berl) (2008) 0.88
Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci (2009) 0.88
A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol (2006) 0.88
Immunohistochemical demonstration of the amphetamine derivatives 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in human post-mortem brain tissues and the pituitary gland. Int J Legal Med (2003) 0.87
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl) (2004) 0.87
Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval. J Clin Exp Neuropsychol (2011) 0.87
Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users. J Neurosci (2009) 0.83
Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One (2013) 0.83
Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PLoS One (2013) 0.83
Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naïve controls. Psychopharmacology (Berl) (2007) 0.83
The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine. J Urban Health (2002) 0.82
Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology (Berl) (2003) 0.81
Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord (2012) 0.80
Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine ("Ecstasy")/polydrug users. Psychopharmacology (Berl) (2011) 0.80
Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users. PLoS One (2010) 0.78
Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing. Psychopharmacology (Berl) (2012) 0.78
3,4-methylenedioxymethamphetamine (MDMA): current perspectives. Subst Abuse Rehabil (2013) 0.78
Illicit stimulant use in humans is associated with a long-term increase in tremor. PLoS One (2012) 0.78
Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology (Berl) (2013) 0.78
Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. Psychopharmacology (Berl) (2009) 0.77
MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRI. Br J Pharmacol (2013) 0.77
The effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in recreational users and animals. PLoS One (2012) 0.77
Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI. Psychopharmacology (Berl) (2014) 0.77
Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice. ACS Chem Neurosci (2010) 0.77
Effect of ecstasy use on neuropsychological function: a study in Hong Kong. Psychopharmacology (Berl) (2005) 0.77
Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. Psychopharmacology (Berl) (2011) 0.76
3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus. Neuroscience (2008) 0.76
Could MDMA Promote Stemness Characteristics in Mouse Embryonic Stem Cells via mGlu5 Metabotropic Glutamate Receptors? Cell J (2012) 0.76
Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. Psychopharmacology (Berl) (2004) 0.76
The impact of positive and negative ecstasy-related information on ecstasy use among college students: Results of a longitudinal study. Drugs (Abingdon Engl) (2010) 0.75
The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology (Berl) (2016) 0.75
"Ecstasy"-induced neurotoxicity: the contribution of functional brain imaging. Eur J Nucl Med Mol Imaging (2006) 0.75
Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study. Front Neurosci (2015) 0.75
Mapping the connectivity of serotonin transporter immunoreactive axons to excitatory and inhibitory neurochemical synapses in the mouse limbic brain. Brain Struct Funct (2016) 0.75
5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study. PLoS One (2015) 0.75
Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet (1998) 5.85
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A (1999) 3.82
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA (1997) 3.35
Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci (1998) 2.40
Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol (1993) 2.25
Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology (1998) 2.00
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. Arch Gen Psychiatry (1989) 1.86
Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res (1982) 1.70
Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res (1980) 1.70
Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res (1980) 1.64
Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology (1994) 1.60
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol (1986) 1.56
Caveat emptor: editors beware. Neuropsychopharmacology (2001) 1.51
Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res (1989) 1.48
Post-myocardial infarction depression. Evid Rep Technol Assess (Summ) (2005) 1.40
Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs. Intensive Care Med (1996) 1.38
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction (1994) 1.22
(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology (2000) 1.20
Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) (1999) 1.12
Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder. Biol Psychiatry (2001) 1.11
Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res (1984) 1.10
Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders. Psychopharmacology (Berl) (2001) 1.08
(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology (2000) 1.04
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol (1991) 1.01
Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res (1987) 1.01
In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain. Synapse (1998) 1.01
Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci (2000) 0.98
Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression. Pain (1985) 0.96
In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse (1993) 0.95
Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse (1992) 0.95
Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience (1989) 0.94
Anatomical distribution of phenolic and tyrosyl ring iodothyronine deiodinases in the nervous system of normal and hypothyroid rats. Endocrinology (1981) 0.94
Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity. J Neurochem (2001) 0.93
Assessing long-term effects of MDMA (Ecstasy). Lancet (2001) 0.92
Neurochemical similarities between d,l-cathinone and d-amphetamine. Drug Alcohol Depend (1982) 0.91
Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci (1992) 0.90
Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. J Pharmacol Exp Ther (2000) 0.90
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology (Berl) (1999) 0.90
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res (1986) 0.89
Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse (1995) 0.89
Repetitive transcranial magnetic stimulation for posttraumatic stress disorder. Arch Gen Psychiatry (1998) 0.89
Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab (1999) 0.89
Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res (1988) 0.88
In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse (1992) 0.88
Effects of intravenous caffeine administered to healthy males during sleep. Depress Anxiety (1997) 0.88
Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett (2000) 0.87
Neural plasticity and emotional memory. Dev Psychopathol (1998) 0.86
Iodothyronine deiodination reaction types in several rat tissues: effects of age, thyroid status, and glucocorticoid treatment. Endocrinology (1984) 0.85
Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf (1996) 0.85
Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep (1993) 0.84
Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem (2001) 0.84
Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine. Neuropharmacology (1983) 0.84
A murine dopamine neuron-specific cDNA library and microarray: increased COX1 expression during methamphetamine neurotoxicity. Neurobiol Dis (2001) 0.84
Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett (1985) 0.84
Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. Chem Res Toxicol (1992) 0.84
A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. J Nucl Med (1993) 0.84
Repetitive transcranial magnetic stimulation as a neuropsychiatric tool: present status and future potential. J ECT (1999) 0.82
Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther (1993) 0.82
Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology (1992) 0.81
Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons. Brain Res (1991) 0.81
Positron emission tomography of 5-HT transporter sites in the baboon brain with [11C]McN5652. J Cereb Blood Flow Metab (1995) 0.80
[123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse (1992) 0.80
Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology (1980) 0.80
Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res (1992) 0.80
Modulating role of dopamine on anesthetic requirements. Eur J Pharmacol (1990) 0.79
Neurotoxins, parkinsonism and Parkinson's disease. Pharmacol Ther (1987) 0.79
Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons. Neurotox Res (2001) 0.79
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur J Pharmacol (1987) 0.79
Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. Neuroreport (1998) 0.79
Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology (1987) 0.79
Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study. Eur Addict Res (2002) 0.79
Chronic pain and depression. I. Classification of depression in chronic low back pain patients. Pain (1985) 0.78
"Ecstasy" and serotonin neurotoxicity: new findings raise more questions. Arch Gen Psychiatry (2001) 0.78
Nerve terminal degeneration after a single injection of D-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion. Brain Res (1984) 0.78
Fenfluramine-induced loss of serotonin transporters in baboon brain visualized with PET. Synapse (1996) 0.78
Chronic idiopathic ataxic neuropathy: neuropathology of a case. Acta Neuropathol (1989) 0.77
Thalamic hemorrhage with neglect and memory disorder. J Neurol Sci (1986) 0.77
Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: importance of dose, species and drug. J Pharmacol Exp Ther (1997) 0.77
Fenfluramine's appetite suppression and serotonin neurotoxicity are separable. Eur J Pharmacol (1995) 0.77
Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeys. Psychopharmacology (Berl) (1992) 0.76
Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull (1995) 0.76
The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat. Pharmacol Biochem Behav (1991) 0.76
Development of PET/SPECT ligands for the serotonin transporter. NIDA Res Monogr (1994) 0.76
MDMA ("ecstasy") and panic disorder: induction by a single dose. Biol Psychiatry (1992) 0.76
Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine. Neuropharmacology (1983) 0.76
N-methylation dissociates methamphetamine's neurotoxic and behavioral pharmacologic effects. Brain Res (1997) 0.76
The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age. Brain Res (1989) 0.75
Responses to i.v. L-tryptophan in MDMA users. NIDA Res Monogr (1989) 0.75